Are sales representatives and the sale strategies of pharmaceutical companies getting too aggressive towards physicians?
In the last few years a number of drugs have been launched into the oncological market by pharmaceutical companies, including new biological drugs and drugs that can be used as a support for patients undergoing cytotoxic chemotherapy. As a matter of fact, pharmaceutical companies are merging, and, through the merging process, the portfolio of the new companies changes and sales representatives are rearranged throughout the new companies. Some of the sales representatives are now afraid of losing their job, due to the changing scenario and the possible lay offs. On the other hand, the new, bigger, pharmaceutical companies are competing more and more with one another, and, in order to stress their products, might adopt a more aggressive sales strategy. For example, sometimes in the same geographical area there are five representatives for just one company, or different representatives for the same drug in different settings. As a result of the new, aggressive strategy, the aggressiveness
Related Questions
- Do the Privacy Rules require physicians to have pharmaceutical sales representatives sign any type of confidentiality agreement, even one that is not a Business Associate Agreement?
- Are sales representatives and the sale strategies of pharmaceutical companies getting too aggressive towards physicians?
- Are physicians required to have pharmaceutical sales representatives sign Business Associate Agreements?
